AGIO

Agios Pharmaceuticals, Inc. (AGIO) | Rumor.io

Agios Pharmaceuticals

AGIO

Attention (50-day avg)0%

Attention rank (50-day avg)#2,700

Bullish sentiment (50-day avg)14%

Price to earnings ratio3.82

Market capitalization2B

Earnings per share-6.74

Dividend yield (TTM)—

Revenue (annual)54M

Net income (annual)-412.8M

Social

What share of all stock conversation is about AGIO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% +0

Jul 30

Agios Pharmaceuticals' Q2 2026 revenue surged 259% YoY to $44.7 million, driven by the strong US launch of AQVESME in thalassemia.
Mitapivat revenue more than doubled sequentially to $44.7 million, with the AQVESME launch gaining traction.
The FDA has granted Mitapivat Priority Review, with a PDUFA date of November 1, 2026, while the company's cash, cash equivalents, and marketable securities totaled $964.8 million.

Generated by AI

Sentiment

Of the messages about AGIO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% new	10.95% -32.48
Bearish	—	—	0% -100	89.05% +32.48

Bullish· Dec 24

The FDA's approval of Agios Pharmaceuticals' anemia drug Aqvesme has unlocked fresh revenue potential and is boosting Wall Street optimism, with price targets drifting higher.
Agios Pharmaceuticals has a strong balance sheet with around $1 billion in cash and equivalents, providing a solid foundation for future growth.
The company's rare-disease franchise is expected to expand, with analysts betting on a bigger business for Agios, which could lead to increased revenue and stock price appreciation.

Bearish· Nov 19

Agios Pharmaceuticals' upcoming PDUFA for PYRUKYND on Dec 7th is not a guarantee of approval, which may continue to weigh on the stock.
The company's Phase 3 results in SCD showed mixed signals, with the primary endpoint not being met, and the stock is trading as if this was the only program in development.
Agios Pharmaceuticals' CEO, Goff, is underperforming and on track to set a new 3-year low, similar to the previous CEO, Fouse.

Generated by AI

Topics

Of the messages about AGIO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	12.32%
Analysts	—	—	—	29.42%
Earnings	—	—	—	28.22%
Controversies	—	—	—	0.01%
Technical Analysis	—	—	—	0.57%
Macro	—	—	—	29.47%

Earnings· Nov 1

Agios Pharmaceuticals ($AGIO) reported a loss of $1.63 per share, missing the estimated loss of $1.69 per share.
The company's FQ3 earnings report also missed revenue estimates by $1.25 million.
Agios Pharmaceuticals' third-quarter earnings results were $-1.63 EPS and $15.20 million in revenue.

Analysts· Jun 15

Citigroup raised Agios Pharmaceuticals' price target to $75, maintaining a Buy rating.
Piper Sandler raised the price target to $80, while SVB Leerink and Guggenheim Securities raised their targets to $72 and $66, respectively.
Oppenheimer Holdings Inc. reaffirmed a hold rating for Agios Pharmaceuticals, while Agios Pharmaceuticals' price target was raised by multiple analysts, including Citigroup, SVB Leerink, and Guggenheim Securities.

Announcements· Dec 24

The FDA has approved Agios Pharmaceuticals' AQVESME (mitapivat) for the treatment of anemia in adults with alpha- or beta-thalassemia, making it the only FDA-approved therapy for both transfusion-dependent and non-transfusion-dependent alpha and beta thalassemia.
The approval is based on Phase 3 trials that met all key primary and secondary efficacy endpoints, showing improvements in hemolytic anemia and quality-of-life measures versus placebo.
AQVESME is expected to be available in late January 2026, following implementation of a required Risk Evaluation and Mitigation Strategy (REMS) program, and is expected to generate peak sales potential of $320M, according to Truist analyst Gregory Renza.

Generated by AI

Community

Of the messages about AGIO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	66.67%	10.89%
Newcomers	—	0%	33.33%	89.11%

Regulars· Jul 21

Agios Pharmaceuticals will discontinue its sickle cell disease candidate, tebapivat, after Phase 2 results failed to show a differentiated profile, with the company citing the asset's inability to establish a level of differentiation necessary for continued development.
The company's Phase 2 trial for tebapivat in adults with sickle cell disease did not meet expectations, with the trial failing to show a significant improvement over the control group, leading Agios to decide against advancing the asset.
Agios will not advance tebapivat in sickle cell disease after Phase 2 results failed to show a differentiated profile, and the company will focus on its other assets, including mitapivat, which has a more advanced profile in the same indication.

Newcomers· Dec 24

The FDA has approved Agios Pharmaceuticals' AQVESME (mitapivat) as the only oral therapy for anemia in adult alpha- or beta-thalassemia, which could unlock peak sales potential of $320M according to Truist analyst Gregory Renza.
Agios' strong balance sheet, with over $1B in cash and equivalents, and no debt, makes it an attractive investment opportunity with a potential risk-reward ratio.
The FDA approval of AQVESME has the potential to significantly boost Agios' revenue, with the company's shares surging nearly 12% premarket, and price targets drifting higher as analysts bet on a bigger rare-disease franchise for Agios.

Generated by AI

News

Agios Pharmaceuticals: Indication Stacking Is Creating A Commercial Flywheel (NASDAQ:AGIO)

1mo agoSeeking Alpha

Devastating Greek wildfires stoke fear of faulty power lines

1mo agoReuters

Cantor Fitzgerald reiterates Agios Pharma stock Overweight rating

1mo agoInvesting.com

Analysts Conflicted on These Healthcare Names: GE Healthcare Technologies Inc (GEHC), Vertex Pharmaceuticals (VRTX) and Agios Pharma (AGIO)

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Agios Pharma (AGIO), Novavax (NVAX) and Keros Therapeutics (KROS)

Detailed price information for Keros Therapeutics Inc (KROS-Q) from The Globe and Mail including charting and trades.

1mo agotheglobeandmail.com

Hundreds escape Greek wildfire by sea as blazes continue across Europe

Around 500 people, mostly tourists, are evacuated by boat from Agios Vasileios after becoming trapped.

2mo agoBBC

Also Discussed

Investors talking about AGIO also mention

#	Name	Attention
1	Alnylam Pharmaceuticals, Inc.ALNY	0%0
2	BioMarin Pharmaceutical IncBMRN	0%+0
3	BLUE - bluebird bio, Inc.	——
4	RDUS - Radius Recycling, Inc.	——
5	Ionis Pharmaceuticals, Inc.IONS	0%new
6	Alkermes plcALKS	0%0
7	BPMC - Blueprint Medicines Corporation	——
8	Cellectis S.A. ADRCLLS	0%0
9	Incyte Corp.INCY	0%new
10	Acadia Pharmaceuticals Inc.ACAD	0%+0

Agios Pharmaceuticals, Inc.

Healthcare
Biotechnology

Agios Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing medicines for rare diseases through its expertise in cellular metabolism. The company’s core commercial product is PYRUKYND (mitapivat), an oral pyruvate kinase activator used in hemolytic anemia associated with pyruvate kinase deficiency, with additional development in other hematologic and genetically defined disorders. Agios is also advancing investigational therapies for conditions such as thalassemia, sickle cell disease, and phenylketonuria, reflecting its emphasis on rare disease biology and precision medicine. The company operates as a specialized hematology and rare disease developer, combining drug discovery, clinical development, and commercialization capabilities to address unmet medical needs. Agios Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.

Website

Location

88 Sidney Street

Cambridge, MA, 02139

United States

Social

What share of all stock conversation is about AGIO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% +0

Jul 30

Agios Pharmaceuticals' Q2 2026 revenue surged 259% YoY to $44.7 million, driven by the strong US launch of AQVESME in thalassemia.
Mitapivat revenue more than doubled sequentially to $44.7 million, with the AQVESME launch gaining traction.
The FDA has granted Mitapivat Priority Review, with a PDUFA date of November 1, 2026, while the company's cash, cash equivalents, and marketable securities totaled $964.8 million.

Generated by AI

Sentiment

Of the messages about AGIO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% new	10.95% -32.48
Bearish	—	—	0% -100	89.05% +32.48

Bullish· Dec 24

The FDA's approval of Agios Pharmaceuticals' anemia drug Aqvesme has unlocked fresh revenue potential and is boosting Wall Street optimism, with price targets drifting higher.
Agios Pharmaceuticals has a strong balance sheet with around $1 billion in cash and equivalents, providing a solid foundation for future growth.
The company's rare-disease franchise is expected to expand, with analysts betting on a bigger business for Agios, which could lead to increased revenue and stock price appreciation.

Bearish· Nov 19

Agios Pharmaceuticals' upcoming PDUFA for PYRUKYND on Dec 7th is not a guarantee of approval, which may continue to weigh on the stock.
The company's Phase 3 results in SCD showed mixed signals, with the primary endpoint not being met, and the stock is trading as if this was the only program in development.
Agios Pharmaceuticals' CEO, Goff, is underperforming and on track to set a new 3-year low, similar to the previous CEO, Fouse.

Generated by AI

Topics

Of the messages about AGIO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	12.32%
Analysts	—	—	—	29.42%
Earnings	—	—	—	28.22%
Controversies	—	—	—	0.01%
Technical Analysis	—	—	—	0.57%
Macro	—	—	—	29.47%

Earnings· Nov 1

Agios Pharmaceuticals ($AGIO) reported a loss of $1.63 per share, missing the estimated loss of $1.69 per share.
The company's FQ3 earnings report also missed revenue estimates by $1.25 million.
Agios Pharmaceuticals' third-quarter earnings results were $-1.63 EPS and $15.20 million in revenue.

Analysts· Jun 15

Citigroup raised Agios Pharmaceuticals' price target to $75, maintaining a Buy rating.
Piper Sandler raised the price target to $80, while SVB Leerink and Guggenheim Securities raised their targets to $72 and $66, respectively.
Oppenheimer Holdings Inc. reaffirmed a hold rating for Agios Pharmaceuticals, while Agios Pharmaceuticals' price target was raised by multiple analysts, including Citigroup, SVB Leerink, and Guggenheim Securities.

Announcements· Dec 24

The FDA has approved Agios Pharmaceuticals' AQVESME (mitapivat) for the treatment of anemia in adults with alpha- or beta-thalassemia, making it the only FDA-approved therapy for both transfusion-dependent and non-transfusion-dependent alpha and beta thalassemia.
The approval is based on Phase 3 trials that met all key primary and secondary efficacy endpoints, showing improvements in hemolytic anemia and quality-of-life measures versus placebo.
AQVESME is expected to be available in late January 2026, following implementation of a required Risk Evaluation and Mitigation Strategy (REMS) program, and is expected to generate peak sales potential of $320M, according to Truist analyst Gregory Renza.

Generated by AI

Community

Of the messages about AGIO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	66.67%	10.89%
Newcomers	—	0%	33.33%	89.11%

Regulars· Jul 21

Agios Pharmaceuticals will discontinue its sickle cell disease candidate, tebapivat, after Phase 2 results failed to show a differentiated profile, with the company citing the asset's inability to establish a level of differentiation necessary for continued development.
The company's Phase 2 trial for tebapivat in adults with sickle cell disease did not meet expectations, with the trial failing to show a significant improvement over the control group, leading Agios to decide against advancing the asset.
Agios will not advance tebapivat in sickle cell disease after Phase 2 results failed to show a differentiated profile, and the company will focus on its other assets, including mitapivat, which has a more advanced profile in the same indication.

Newcomers· Dec 24

The FDA has approved Agios Pharmaceuticals' AQVESME (mitapivat) as the only oral therapy for anemia in adult alpha- or beta-thalassemia, which could unlock peak sales potential of $320M according to Truist analyst Gregory Renza.
Agios' strong balance sheet, with over $1B in cash and equivalents, and no debt, makes it an attractive investment opportunity with a potential risk-reward ratio.
The FDA approval of AQVESME has the potential to significantly boost Agios' revenue, with the company's shares surging nearly 12% premarket, and price targets drifting higher as analysts bet on a bigger rare-disease franchise for Agios.

Generated by AI

Agios Pharmaceuticals

Social

Jul 30

Bullish· Dec 24

Bearish· Nov 19

Earnings· Nov 1

Analysts· Jun 15

Announcements· Dec 24

Regulars· Jul 21

Newcomers· Dec 24

Agios Pharmaceuticals: Indication Stacking Is Creating A Commercial Flywheel (NASDAQ:AGIO)

Devastating Greek wildfires stoke fear of faulty power lines

Cantor Fitzgerald reiterates Agios Pharma stock Overweight rating

Analysts Conflicted on These Healthcare Names: GE Healthcare Technologies Inc (GEHC), Vertex Pharmaceuticals (VRTX) and Agios Pharma (AGIO)

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Agios Pharma (AGIO), Novavax (NVAX) and Keros Therapeutics (KROS)

Hundreds escape Greek wildfire by sea as blazes continue across Europe

Also Discussed

Agios Pharmaceuticals, Inc.

Company Information

Location

Agios Pharmaceuticals: Indication Stacking Is Creating A Commercial Flywheel (NASDAQ:AGIO)

Devastating Greek wildfires stoke fear of faulty power lines

Cantor Fitzgerald reiterates Agios Pharma stock Overweight rating

Analysts Conflicted on These Healthcare Names: GE Healthcare Technologies Inc (GEHC), Vertex Pharmaceuticals (VRTX) and Agios Pharma (AGIO)

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Agios Pharma (AGIO), Novavax (NVAX) and Keros Therapeutics (KROS)

Hundreds escape Greek wildfire by sea as blazes continue across Europe

Also Discussed

Social

Jul 30

Bullish· Dec 24

Bearish· Nov 19

Earnings· Nov 1

Analysts· Jun 15

Announcements· Dec 24

Regulars· Jul 21

Newcomers· Dec 24